Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Companyā€™s leading š¯›¼-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranosticā€¯ approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. The Companyā€™s melanoma (VMT01) and neuroendocrine tumor (VMT-š¯›¼-NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions.
Looking for a particular Viewpoint Molecular Targeting, Inc. employee's phone or email?
Viewpoint Molecular Targeting, Inc. Questions
The Viewpoint Molecular Targeting, Inc. annual revenue was $5 million in 2026.
3 people are employed at Viewpoint Molecular Targeting, Inc..
Viewpoint Molecular Targeting, Inc. is based in Coralville, Iowa.
The NAICS codes for Viewpoint Molecular Targeting, Inc. are [325, 3254, 32541, 32].
The SIC codes for Viewpoint Molecular Targeting, Inc. are [283, 28].
Top Viewpoint Molecular Targeting, Inc. Employees
Related Companies
